← Back to Clinical Trials
Recruiting NCT06935786

NCT06935786 SEDentary Lifestyle, Mortality and Major Adverse Clinical Outcomes in Chronic KIDney Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06935786
Status Recruiting
Phase
Sponsor Turku University Hospital
Condition Chronic Kidney Disease
Study Type INTERVENTIONAL
Enrollment 400 participants
Start Date 2025-02-21
Primary Completion 2031-12-31

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
EXERCISE TRAINING WITH OR WITHOUT MEDICATION

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 400 participants in total. It began in 2025-02-21 with a primary completion date of 2031-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to learn if a simple home exercise program can benefit patients with advanced chronic kidney disease. There is also an observational part of the study without an exercise program. The study will record patients' mortality, cardiovascular events, emergency department visits, hospital stays, need for dialysis and 6 minutes walking distance. Also maximal oxygen uptake, quality of life and bone fractures are recorded and blood tests and X-rays analyzed. The prospective observational part of the study will investigate the link between cardiovascular and kidney health as well as exercise capacity and adverse outcomes.

Eligibility Criteria

Inclusion Criteria: * Age \>40 years * Estimated glomerular filtration rate \< 20ml/min/1.73m2 (CKD stage 4-5) * Informed consent from the patient is received Exclusion Criteria: * Maintenance dialysis dependency before inclusion * Pregnant women * Patient's lack of commitment to follow-up * Chronic or acute clinical condition with a prognosis less than 6 months * Amputated lower limbs

Contact & Investigator

Central Contact

Markus Hakamäki, MD, PhD

✉ markus.hakamaki@tyks.fi

📞 +35823130000

Principal Investigator

Tapio Hellman, MD, PhD

PRINCIPAL INVESTIGATOR

Turku University Hospital and University of Turku

Frequently Asked Questions

Who can join the NCT06935786 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, studying Chronic Kidney Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06935786 currently recruiting?

Yes, NCT06935786 is actively recruiting participants. Contact the research team at markus.hakamaki@tyks.fi for enrollment information.

Where is the NCT06935786 trial being conducted?

This trial is being conducted at Pori, Finland, Turku, Finland, Vaasa, Finland.

Who is sponsoring the NCT06935786 clinical trial?

NCT06935786 is sponsored by Turku University Hospital. The principal investigator is Tapio Hellman, MD, PhD at Turku University Hospital and University of Turku. The trial plans to enroll 400 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology